--- title: "HHS submits peptide drug policy for White House review" publication: "MediaBias News" url: "https://mediabias.news/politics/hhs-submits-peptide-drug-policy-for-white-house-review" api: "https://mediabias.news/api/v1/stories/hhs-submits-peptide-drug-policy-for-white-house-review" markdown: "https://mediabias.news/politics/hhs-submits-peptide-drug-policy-for-white-house-review.md" audio: "https://mediabias.news/api/audio/hhs-submits-peptide-drug-policy-for-white-house-review" category: "Politics" published: "2026-10-18T04:05:28.638Z" source_reported: "2026-10-17T17:45:35.000Z" updated: "2026-10-18T04:05:28.638Z" trust_score: 42 critic_score: 57 hype_score: 41 assessment_type: "coverage-and-source-reporting-analysis" fact_check_status: "not-performed" coverage_measured: "2026-10-18T02:41:17.902Z" --- # HHS submits peptide drug policy for White House review *The proposed policy could allow the FDA to exercise enforcement discretion on certain peptide medications.* **Scores for the source reporting** (0-100, assessing the original journalism this article was written from, not this write-up): - Trust 42 of 100, higher is better. Central claim attributed to named bodies, but relies on anonymous sourcing and lacks specific dates and locations. - Craft 57 of 100, higher is better. Quotes affected parties and names specific entities, but lacks detail on what happens next or what is unknown. - Hype 41 of 100, lower is better. Headline promises more than the body delivers, with mild emphasis and a lively but fair headline. Scored by MediaBias News; method at https://mediabias.news/methodology. **The short version** - The Department of Health and Human Services (HHS) has submitted an action plan for peptide medication to the Office of Management and Budget (OMB) for review. - The American Academy of Peptide Medicine (AAPM) is the listed requestor for the policy, which aims to provide interim access to certain peptide drugs. - FDA staff scientists have previously raised concerns about the safety and efficacy of some peptide drugs, stating they may cause harm. - The proposed policy could grant the FDA "enforcement discretion," allowing it to decide whether to enforce current restrictions on these drugs. The Department of Health and Human Services (HHS) has submitted a policy plan concerning peptide medications to the Office of Management and Budget (OMB) for review. The American Academy of Peptide Medicine (AAPM) is identified as the requestor for this policy, titled "Interim Access Policy for Compounding Certain Peptides." This submission follows the FDA's Pharmacy Compounding Advisory Committee's vote in July to approve six out of seven peptides considered. FDA staff scientists have previously expressed concerns that certain peptide drugs have not undergone sufficient study to confirm their safety and effectiveness, and may pose risks. The proposed policy could allow the FDA to exercise "enforcement discretion," meaning the agency could choose not to enforce existing restrictions on some of these peptide drugs. ## Disagreement on policy's aim The WND report states that the policy is a "priority plan to put peptides in pharmacies" and quotes AAPM chair Lee Rosebush saying the posting is a "welcome signal that the process is moving forward" and that they "urge HHS and FDA to place these substances on the interim bulk drug substances lists, which would give patients a safe, legitimate source and help eliminate the black and gray markets." Ars Technica reports that the policy would "ease access to unproven peptide drugs" and that FDA staff scientists found the drugs "have not been sufficiently studied to establish safety and efficacy and may cause harms." ## What the coverage left out None of the right-rated reports mention the concerns raised by FDA staff scientists regarding the safety and efficacy of certain peptide drugs, nor do they include statements from advocacy groups like the Center for Science in the Public Interest that warned of potential harm to consumers. The centre-rated report from Ars Technica included these details. ## Who covered it Shares of the 9 covering outlets with a published leaning rating: - Left: 0% (0) - Centre: 11% (1) - Right: 89% (8) 2 of 11 covering outlets carried no usable leaning rating and were excluded from those percentages. Coverage measured 2026-10-18T02:41:17.902Z. **Coverage watch:** developing. Checked 9 times; 0 checks found a material change. Most recently checked 2026-10-18T06:15:18.938Z. ## How the sides framed it ### Left No separate framing summary. ### Centre - Ars Technica led on the potential for the policy to ease access to unproven peptide drugs, despite concerns from FDA staff scientists about their safety and efficacy. The report noted that the policy could give the FDA "enforcement discretion" on certain peptide drugs, allowing it to choose not to enforce current restrictions. It also highlighted that many prominent figures in the Make America Healthy Again movement, associated with Health Secretary Robert F. Kennedy Jr., sell peptide products. The outlet quoted Pete Lurie, president of the Center for Science in the Public Interest, calling the committee's recommendations potentially harmful to consumers. ### Right - Reports from right-rated outlets, including WND and The Daily Caller, focused on the submission of the "Interim Access Policy for Compounding Certain Peptides" to the OMB as a priority plan to get peptides into pharmacies. These reports quoted AAPM chair Lee Rosebush expressing encouragement and urging the placement of substances on interim bulk drug lists for safe, legitimate access and to combat black and gray markets. WND also noted that Robert F. Kennedy Jr. reaffirmed his dedication to getting peptides approved for patients in an April post on his X account. **Provisional coverage gap:** left. The watch is not closed, so this is not yet a settled blindspot finding. ## Factuality profile of the covering outlets These are published factuality ratings of the outlets, not a verdict on whether this story or its claims are true. - veryLow: 1 - low: 3 - mixed: 4 - unknown: 2 - veryHigh: 1 ## Verification scope This page compares coverage and scores the source reporting. It is not a ClaimReview verdict on whether the underlying event or claim is true. ## Original reporting this was written from - [OpsLens](https://opslens.com/rfk-jr-s-priority-plan-to-put-peptides-in-pharmacies-pushed-to-white-house-worldnetdaily-by-libby-bandelin-daily-caller-news-foundation) — RFK Jr.’s priority plan to put peptides in pharmacies pushed to White House * WorldNetDaily * by Libby Bandelin, Daily Caller News Foundation - [WND](https://wnd.com/2026/10/rfk-jr-s-priority-plan-put-peptides-pharmacies) — RFK Jr.’s priority plan to put peptides in pharmacies pushed to White House * WorldNetDaily * by Libby Bandelin, Daily Caller News Foundation - [modernity.news](https://modernity.news/2026/10/17/rfk-jr-s-priority-plan-to-put-peptides-in-pharmacies-pushed-to-white-house) — RFK Jr.’s Priority Plan To Put Peptides In Pharmacies Pushed To White House - [🔔 The Liberty Daily](https://thelibertydaily.com/rfk-jr-s-priority-plan-put-peptides-pharmacies) — RFK Jr.'s Priority Plan to Put Peptides in Pharmacies Pushed to White House - [The Daily Caller](https://dailycaller.com/2026/10/16/rfk-jr-peptides-pharmacies-hhs-action-plans) — RFK Jr’s Priority Plan To Put Peptides In Pharmacies Pushed To White House - [thedailybs.com](https://thedailybs.com/2026/10/16/rfk-jr-s-priority-plan-to-put-peptides-in-pharmacies-pushed-to-white-house) — RFK Jr.’s priority plan to put peptides in pharmacies pushed to White House - The Daily Bo Snerdley - [themondonews.com](https://themondonews.com/technology/rfk-jr-urges-fda-to-ignore-unproven-peptides-according-to-report) — RFK Jr. Urges FDA to Ignore Unproven Peptides, According to Report - [Ars Technica](https://arstechnica.com/health/2026/10/rfk-jr-proposes-fda-look-the-other-way-on-unproven-peptides-report-says) — RFK Jr. proposes FDA look the other way on unproven peptides, report says - [endpoints.news](https://endpoints.news/fda-considers-interim-access-for-compounded-peptides-enspryngs-label-expansion) — FDA considers interim access for compounded peptides; Enspryng's label expansion - [105.9 FM and AM 630—Where Washington Comes To Talk | WMAL-AF…](https://wmal.com/2026/10/16/hhs-proposes-letting-pharmacies-make-peptides) — HHS Proposes Letting Pharmacies Make Peptides - [Washington Times](https://washingtontimes.com/news/2026/oct/16/hhs-proposes-letting-pharmacies-make-peptides) — HHS proposes letting pharmacies make peptides ## Questions **What is the proposed policy regarding peptide medications?** The Department of Health and Human Services has submitted an "Interim Access Policy for Compounding Certain Peptides" to the Office of Management and Budget for review. This policy could allow the FDA to exercise "enforcement discretion," meaning it might choose not to enforce current restrictions on certain peptide drugs. **Who requested this policy?** The American Academy of Peptide Medicine (AAPM) is listed as the requestor for the proposed policy. AAPM is a nonprofit academic society dedicated to advancing the responsible clinical use of peptide therapies. **What concerns have been raised about these peptide drugs?** FDA staff scientists have indicated that certain peptide drugs have not been sufficiently studied to establish their safety and efficacy and may cause harms. Advocacy groups have also warned that unproven peptides could put consumers at risk of serious injury. --- MediaBias News — https://mediabias.news. Reproduced from https://mediabias.news/politics/hhs-submits-peptide-drug-policy-for-white-house-review. Please cite as: MediaBias News, "HHS submits peptide drug policy for White House review", https://mediabias.news/politics/hhs-submits-peptide-drug-policy-for-white-house-review